Atropine low concentration is an evolving treatment for myopia progression, but its effectiveness and optimum concentration remain unclear. The current study was conducted to assess the effectiveness and protection of low-concentration atropine for one year with different doses, and a placebo was used as a control. For this purpose, a double-blind single-centered clinical trial consisting of 132 children (subjects), aged (5-13) years with myopic refraction of at least −1.0 D in both eyes, astigmatism of less than −2.5 D and confirmed myopic development of at least 0.5 D for 1 year were performed